Colonna S, Curtin K, Johnson E, Kohlmann W, Wright J, et al. (2019) Family History of Breast Cancer Associated with Breast Cancer in Survivors of Hodgkin Lymphoma. Int J Cancer Clin Res 6:107.


© 2019 Colonna S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ORIGINAL RESEARCH | OPEN ACCESSDOI: 10.23937/2378-3419/1410107

Family History of Breast Cancer Associated with Breast Cancer in Survivors of Hodgkin Lymphoma

Sarah Colonna1,2,3, Karen Curtin1,2, Eric Johnson1,2*, Wendy Kohlmann1, Jennifer Wright1,4, Anne Kirchhoff4, Sean Tavtigian1 and Joshua Schiffman1,4

1Huntsman Cancer Institute, The University of Utah, USA

2Department of Internal Medicine, The University of Utah, USA

3George E. Wahlen Department of VA, Salt Lake City, Utah, USA

4Department of Pediatrics, The University of Utah, USA



Advances in treatments for Hodgkin Lymphoma (HL) have significantly increased survival of childhood and adult patients; however, the leading cause of death in HL survivors is due to secondary malignancy following HL treatment [1,2]. Among women treated for HL, breast cancer (BC) is the most common secondary malignancy [3]. We explored if an association exists between HL and BC exists within families.


Utilizing the Utah Population Database and the Utah Cancer Registry, we identified 988 women with HL, and no history of BC prior to HL, diagnosed in Utah from 1966-2014. We examined if women with HL were at greater risk of developing BC based on the presence or absence of family history of BC. We also examined the familial recurrence risk of BC among female FDRs of women with HL and BC using Cox regression methods.


Among 988 female HL patients, 42 (4.3%) were diagnosed with subsequent BC while among 9,876 matched controls, 280 controls (2.8%) were diagnosed with BC from 1966-2014 (P < 0.05). We observed a significant 3-fold increased risk of BC in the first-degree relatives (parent, full sibling, or child of patient) of female HL patients with subsequent BC, compared to FDR in controls (HR = 2.8, 95%CI 1.4-5.6; P = 0.005). Female HL patients who had a family history of BC were significantly more likely to develop BC, compared to HL patients with no history of BC among relatives (HR = 3.3, 95%CI 1.6-7.1; P = 0.002).


Women with HL and a family history of BC are at even higher than anticipated risk of BC, as are their female relatives. Obtaining a thorough family history for a woman preparing to undergo therapy for HL is important for treatment decisions for HL and maintaining an up to date family history over time is also important for the management of a woman's ongoing cancer risks and her surveillance strategy following survival of HL.